Diamyd Medical (DMYD-B.ST) Stock Analysis & AI Equity Report
Diamyd Medical (DMYD-B.ST) overview
Diamyd Medical (DMYD-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Diamyd Medical reported revenue of SEK 0.1m and operating profit of SEK -147m; the year-end share price was 16.42 SEK and market capitalisation was SEK 1,562m. Diamyd Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Diamyd Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Diamyd Medical
Diamyd Medical AB develops precision medicine therapies for type 1 diabetes, with a focus on the antigen-specific immunotherapy retogatein, based on recombinant GAD65. The company is conducting clinical development in stage 1 to stage 3 disease and is also building manufacturing capacity in Umeå for its active pharmaceutical ingredient and related biologic production.
Generate the Diamyd Medical report
Diamyd Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Diamyd Medical and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.